Month: February 2021

 No. 3/2021Copenhagen, 25 February 2021Development in EBITDAAuction Turnover for the quarter increased 20.3 percent compared to same period 2019. The increase is driven by continued strong commercial initiatives. This convincing growth in Q4 further strengthen the growth of 14 percent executed in Q3. In total a growth of 17 percent was achived in the second half of 2020 compared to 2019.EBITDA in the fourth quarter of 2020 is DKK 13.9m compared to DKK 2.0m previous year driven by increase in revenue as well as a decrease in costs.In total, costs decreased by 4.0 percent compared to Q4 last year. As a result of Lauritz.com taking over a number of auction houses from partners the costs related to these houses change from partner commission (in variable expenses) to salaries and other external expenses.The Cash Flow from Operations in Q4...

Paris, February 25, 2021 – Atos and HDF Energy today announce their plan to develop a complete end-to-end long-term solution to supply datacenters with green hydrogen generated by renewable energy. The new solution by Atos and HDF will be the first available on the market for datacenters with heavy power consuming workloads, with the aim to demonstrate, in 2023, a first full production center operated using green hydrogen. Atos will provide a complete end-to-end green datacenter solution by designing and providing the hardware, software and integration services that make it possible to exploit the electricity produced by green hydrogen so that it can be used in datacenters. This includes using the most advanced Artificial Intelligence (AI) technologies to optimize energy consumption. HDF Energy will supply a power plant, which will provide...

Paris, le 25 février 2021 – Atos et HDF Energy annoncent aujourd’hui leur volonté de développer une solution complète pour alimenter, dans la durée, des datacenters avec de l’hydrogène généré par des énergies renouvelables. La solution devrait être la première disponible sur le marché pour les datacenters à forte consommation énergétique. Les deux entreprises ont pour objectif la mise en opération, dès 2023, d’un premier datacenter fonctionnant à l’hydrogène vert. Atos concevra et fournira le matériel, les logiciels et les services d’intégration qui permettent d’exploiter l’électricité produite à partir d’hydrogène vert, en s’appuyant notamment sur des technologies d’intelligence artificielle (IA) pour optimiser la consommation. HDF apportera la centrale électrique fournissant une électricité prévisible...

Trondheim, 25 February 2021: NORBIT ASA, today announces that NORBIT Subsea, part of segment Oceans, has received an order for multiple WINGHEAD sonars from a leading global survey company. The NORBIT WINGHEADs will be installed on an Unmanned Surface Vessel (USV) to be used on marine renewable energy projects. The value of the order is approximately NOK 10 million, to be delivered during the second quarter of 2021.“We are proud to see that a leading global survey company has chosen to base their innovative platform for unmanned surveying on our WINGHEAD sonar system. The integrated USV based solution provides for a cost efficient carbon neutral surveying capability, particularly suited for marine renewable energy projects,” says Per Jørgen Weisethaunet.The NORBIT WINGHEAD sonar family targets the higher-end professional market demanding...

FULL YEAR GROWTH, Q3 AND Q4 PROFITABLEFourth Quarter 2020                                                                               Full Year 2020        • Net sales: KSEK 5 954 (3 824, +56%)                                                   • Net sales: KSEK  20 488 (18 742, +9%)      • Profit for the period: KSEK 1 095 (-6 131)                                             • Profit for the period KSEK -6 730 (-15 682)• Earnings per share SEK 0,02 (-0,09)                                                     • Earnings per share: SEK -0,09 (-0,23)• Earnings per average number of shares: SEK 0,02 (-0,09)                   • Earnings per average number of shares: SEK -0,10 (-0,24)MESSAGE FROM THE CEOThe last quarter of the year was the second consecutive quarter with both positive cashflow and a positive result. The net sales in Q4 were...

JANUARY – DECEMBER 2020Net sales amounted to MSEK 0.3 (0.0)Operating expenses amounted to MSEK -33.0 (-31.4)Profit/loss before and after tax amounted to MSEK -32.3 (-31.4)Earnings per share amounted to SEK -1.20 (-1.34)Cash flow from operating activities amounted to MSEK -27.4 (-31.2)Equity amounted to MSEK 42.8 (15.5) and the debt/equity ratio was 79% (72%)OCTOBER – DECEMBER 2020Net sales amounted to MSEK 0.3 (0.0)Operating expenses amounted to MSEK -12.9 (-8.5)Profit/loss before and after tax amounted to MSEK -12.5 (-8.5)Earnings per share amounted to SEK -0.42 (-0.36)Cash flow from operating activities amounted to MSEK -10.1 (-9.8)Equity amounted to MSEK 42.8 (15.5) and the debt/equity ratio was 79% (72%)SIGNIFICANT EVENTS DURING THE FORTH QUARTER 2020Intratumoral injection of NZ-TLR9, NanoZolid® formulation of a Toll-Like Receptor...

Westpay’s annual report for 2020 is now available on www.investor.westpay.seWestpay’s annual report for 2020 has today been published on the company’s website and is attached to this release.For the full report, please follow the link:https://investor.westpay.se/financial-reports-2020/annual-report-2020For additional information, please contact:Sten Karlsson, CEO Westpay ABMobile: +46 70-555 6065Email: sten.karlsson@westpay.seLars Levin, CFO Westpay ABMobile: +46 70-8966 404Email: lars.levin@westpay.seWestpay’s Certified Adviser is Erik Penser Bank,phone: +46 8-463 80 00, email: certifiedadviser@penser.seAttachmentsPressrelease_20210225_Westpay_Annual_Report_2020Westpay AB – Årsredovisning 2020

FinanstilsynetNasdaq Copenhagen A/SFebruary 25, 2021Vestjysk Bank A/S refinances hybrid core capitalVestjysk Bank A/S hereby announces that the bank has issued DKK 50 million in hybrid core capital effective on March 12, 2021.The issue has a perpetual structure with the possibility for early redemption after 5 years and has a fixed coupon of 4,75% pro anno during the first 5 years. The issue has the ISIN code DK0030484118.The issue is part of the ongoing process of optimising the capital structure. On March 28, 2021, the proceeds will be used to redeem the existing hybrid loan originally issued by Den Jyske Sparekasse with the ISIN code DK0030298088. Any questions to this announcement must be directed to Jan Ulsø Madsen, CEO, at tel. (+45) 96 63 21 04.Vestjysk Bank A/SJan Ulsø Madsen, CEOVestjysk Bank A/STorvet 4-5DK-7620 LemvigTelephone...

FinanstilsynetNasdaq Copenhagen A/S25. februar 2021Vestjysk Bank A/S omlægger hybrid kernekapitalVestjysk Bank A/S kan hermed meddele, at banken udsteder 50 mio. kr. i hybrid kernekapital med valør den 12. marts 2021.Udstedelsen har uendelig løbetid med mulighed for førtidig indfrielse efter 5 år og forrentes med en fast årlig rente på 4,74 % de første 5 år. Udstedelsen har fondskoden DK0030484118. Udstedelsen sker som en del af den løbende proces med at optimere kapitalstrukturen. Den 28. marts 2021, vil provenuet blive anvendt til indfrielse af nuværende hybridlån oprindeligt udstedt af Den Jyske Sparekasse med fondskode DK0030298088.Eventuelle henvendelser bedes rettes til Jan Ulsø Madsen, CEO, på (+45) 96 63 21 04.Vestjysk Bank A/SJan Ulsø Madsen, CEOVestjysk Bank A/STorvet 4-57620 LemvigTelefon 96 63 20 00CVR-nr. 34 63 13 28www.vestjyskbank.dkVedhæftet...

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that a collaboration agreement has been signed with the R&D and Production company PharmIdea SIA in Riga, Latvia. PharmIdea focuses on anti-cancer drugs and sterile formulations. The collaboration enables LIDDS to expand the manufacturing of new product candidates, e.g. including biomolecules and cytostatics, in addition to the already existing collaboration with Recipharm for Liproca Depot.“We are very pleased to have closed this agreement with a dedicated mid-sized R&D and Production site relatively close to Uppsala and with a long-term experience of production of anti-cancer drugs for European pharmaceutical companies. The agreement allows us to work in parallel with several important product candidates that are close to entering clinical trials,” said Monica Wallter, CEO...